BACK

Made in Australia - COVID-19 vaccine manufacturing explained

This article was published on
February 12, 2021

This explainer is more than 90 days old. Some of the information might be out of date or no longer relevant. Browse our homepage for up to date content or request information about a specific topic from our team of scientists.

As the Australian Government prepares to roll out the COVID-19 vaccination program, CSL has been busily manufacturing the AstraZeneca COVID-19 vaccine (recombinant adenovirus vaccine). CSL has a contract to manufacture 50 million doses of the AstraZeneca vaccine for use by Australians and is on track to deliver the first doses - tested, approved and released by the TGA (subject to TGA approval) – from late March. Representatives from CSL and Seqirus’ advanced manufacturing facilities in Broadmeadows and Parkville, Victoria will explain the process of manufacturing the AstraZeneca vaccine – starting from the first ‘vial thaw’ through to ‘harvest’ of the product in bulk, to formulation and ‘fill and finish’ into dose vials.

As the Australian Government prepares to roll out the COVID-19 vaccination program, CSL has been busily manufacturing the AstraZeneca COVID-19 vaccine (recombinant adenovirus vaccine). CSL has a contract to manufacture 50 million doses of the AstraZeneca vaccine for use by Australians and is on track to deliver the first doses - tested, approved and released by the TGA (subject to TGA approval) – from late March. Representatives from CSL and Seqirus’ advanced manufacturing facilities in Broadmeadows and Parkville, Victoria will explain the process of manufacturing the AstraZeneca vaccine – starting from the first ‘vial thaw’ through to ‘harvest’ of the product in bulk, to formulation and ‘fill and finish’ into dose vials.

Publication

What our experts say

Context and background

Resources

Media briefing

  • Dr Anthony Stowers, Senior Vice President, Recombinant Product Development, CSL
  • Mr Chris Larkins, Senior Vice President, Manufacturing Operations, Seqirus
  • Dr Andrew Nash, Chief Scientific Officer, CSL

Declaration: CSL is a supporter of the Australian Science Media Centre and contributes ~1% of the Centre's budget. More info on our independence can be found on our website.

Media Release

Expert Comments: 

No items found.

Q&A

No items found.